Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(8.18%)
INR 136.85
(8.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.17 Billion INR | 3.94% |
| 2022 | 4.02 Billion INR | 30.78% |
| 2021 | 3.07 Billion INR | 37.7% |
| 2020 | 2.23 Billion INR | -33.57% |
| 2019 | 3.36 Billion INR | 27.62% |
| 2018 | 2.63 Billion INR | -2.96% |
| 2017 | 2.71 Billion INR | -27.31% |
| 2016 | 3.73 Billion INR | 27.73% |
| 2015 | 2.92 Billion INR | -34.82% |
| 2014 | 4.48 Billion INR | 13.46% |
| 2013 | 3.95 Billion INR | 28.37% |
| 2012 | 3.07 Billion INR | 27.49% |
| 2011 | 2.41 Billion INR | 168.21% |
| 2010 | 900.21 Million INR | -44.1% |
| 2009 | 1.61 Billion INR | 73.37% |
| 2008 | 928.9 Million INR | 340.73% |
| 2007 | 210.76 Million INR | 1208.89% |
| 2006 | -19 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 4.02 Billion INR | 866.39% |
| 2023 Q4 | 4.17 Billion INR | 597.82% |
| 2023 Q1 | 416.2 Million INR | -89.65% |
| 2023 Q3 | 598.81 Million INR | -85.11% |
| 2023 FY | 4.17 Billion INR | 3.94% |
| 2022 FY | 4.02 Billion INR | 30.78% |
| 2022 Q1 | 606.9 Million INR | -80.26% |
| 2022 Q2 | 3.88 Billion INR | 540.11% |
| 2022 Q3 | 409.81 Million INR | -89.45% |
| 2022 Q4 | 4.02 Billion INR | 880.99% |
| 2021 Q2 | 2.46 Billion INR | 298.99% |
| 2021 Q1 | 618.51 Million INR | -72.29% |
| 2021 FY | 3.07 Billion INR | 37.7% |
| 2021 Q3 | 664.26 Million INR | -73.08% |
| 2021 Q4 | 3.07 Billion INR | 362.78% |
| 2020 Q4 | 2.23 Billion INR | -24.5% |
| 2020 Q1 | 1.26 Billion INR | -62.46% |
| 2020 Q3 | 2.95 Billion INR | 111.49% |
| 2020 FY | 2.23 Billion INR | -33.57% |
| 2020 Q2 | 1.39 Billion INR | 10.83% |
| 2019 FY | 3.36 Billion INR | 27.62% |
| 2019 Q3 | 921.5 Million INR | -60.53% |
| 2019 Q4 | 3.36 Billion INR | 264.66% |
| 2019 Q1 | 725.09 Million INR | -72.46% |
| 2019 Q2 | 2.33 Billion INR | 221.96% |
| 2018 Q4 | 2.63 Billion INR | 306.57% |
| 2018 Q3 | 647.63 Million INR | -69.08% |
| 2018 FY | 2.63 Billion INR | -2.96% |
| 2018 Q1 | 568.89 Million INR | -79.03% |
| 2018 Q2 | 2.09 Billion INR | 268.18% |
| 2017 Q2 | 3.41 Billion INR | 183.52% |
| 2017 FY | 2.71 Billion INR | -27.31% |
| 2017 Q4 | 2.71 Billion INR | 223.18% |
| 2017 Q3 | 839.61 Million INR | -75.45% |
| 2017 Q1 | 1.2 Billion INR | -67.69% |
| 2016 FY | 3.73 Billion INR | 27.73% |
| 2016 Q3 | 1.18 Billion INR | -65.84% |
| 2016 Q2 | 3.48 Billion INR | 297.72% |
| 2016 Q1 | 875.16 Million INR | -70.05% |
| 2016 Q4 | 3.73 Billion INR | 213.94% |
| 2015 Q3 | 1.61 Billion INR | -35.22% |
| 2015 Q4 | 2.92 Billion INR | 80.88% |
| 2015 Q2 | 2.49 Billion INR | 538.86% |
| 2015 Q1 | 390.38 Million INR | -91.29% |
| 2015 FY | 2.92 Billion INR | -34.82% |
| 2014 FY | 4.48 Billion INR | 13.46% |
| 2014 Q2 | 2.94 Billion INR | 711.56% |
| 2014 Q4 | 4.48 Billion INR | 646.2% |
| 2014 Q3 | 600.82 Million INR | -79.6% |
| 2014 Q1 | 362.9 Million INR | -90.82% |
| 2013 FY | 3.95 Billion INR | 28.37% |
| 2013 Q4 | 3.95 Billion INR | 0.0% |
| 2012 Q2 | 1.78 Billion INR | 0.0% |
| 2012 Q4 | 3.07 Billion INR | 0.0% |
| 2012 FY | 3.07 Billion INR | 27.49% |
| 2011 FY | 2.41 Billion INR | 168.21% |
| 2010 FY | 900.21 Million INR | -44.1% |
| 2009 FY | 1.61 Billion INR | 73.37% |
| 2008 FY | 928.9 Million INR | 340.73% |
| 2007 FY | 210.76 Million INR | 1208.89% |
| 2006 FY | -19 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -8.089% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -13.141% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 246.997% |
| Granules India Limited | 9.28 Billion INR | 55.005% |
| Indoco Remedies Limited | 6.47 Billion INR | 35.478% |
| Achyut Healthcare Limited | -3.74 Million INR | 111649.119% |
| Ajanta Pharma Limited | -954.9 Million INR | 537.599% |
| Alkem Laboratories Limited | -1.6 Billion INR | 359.639% |
| Alpa Laboratories Limited | 35.36 Million INR | -11716.39% |
| Brooks Laboratories Limited | 49.48 Million INR | -8344.236% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 183.365% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -26.665% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 460.926% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 67.64% |
| Eris Lifesciences Limited | 13.8 Billion INR | 69.734% |
| FDC Limited | -57.75 Million INR | 7335.472% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 197.512% |
| Gufic Biosciences Limited | 3.19 Billion INR | -30.815% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 200.616% |
| Ipca Laboratories Limited | 11.41 Billion INR | 63.394% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 400.636% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -116.182% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1930.442% |
| Laurus Labs Limited | 24.38 Billion INR | 82.864% |
| Lupin Limited | 17.19 Billion INR | 75.695% |
| Mankind Pharma Limited | -9.9 Billion INR | 142.174% |
| Medicamen Biotech Limited | 160.31 Million INR | -2506.496% |
| Medico Remedies Limited | 78.67 Million INR | -5211.12% |
| Megasoft Limited | 1.28 Billion INR | -225.046% |
| NATCO Pharma Limited | -5.81 Billion INR | 171.835% |
| Piramal Pharma Limited | 42.27 Billion INR | 90.116% |
| RPG Life Sciences Limited | -364.7 Million INR | 1245.772% |
| Sigachi Industries Limited | 859.94 Million INR | -385.916% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 105.766% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -2782.291% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -8942.501% |
| Unichem Laboratories Limited | 931.91 Million INR | -348.391% |
| Wanbury Limited | 1.1 Billion INR | -277.857% |
| Windlas Biotech Limited | -273.04 Million INR | 1630.409% |
| ZIM Laboratories Limited | 983.6 Million INR | -324.828% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -6.816% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 543.685% |
| Divi's Laboratories Limited | -39.77 Billion INR | 110.507% |
| Hester Biosciences Limited | 2.29 Billion INR | -82.414% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 277.966% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1779.568% |
| Bal Pharma Limited | 1.26 Billion INR | -230.703% |
| Strides Pharma Science Limited | 23.25 Billion INR | 82.033% |
| Venus Remedies Limited | -267.7 Million INR | 1660.938% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -59.984% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 32.135% |
| Shilpa Medicare Limited | 9.06 Billion INR | 53.927% |
| Aarti Drugs Limited | 5.54 Billion INR | 24.688% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 479.427% |
| Suven Life Sciences Limited | -1.63 Billion INR | 355.934% |
| Ind-Swift Limited | 9.5 Billion INR | 56.054% |
| Valiant Laboratories Limited | -295.03 Million INR | 1516.331% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -48.115% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 58.335% |
| Themis Medicare Limited | 764.96 Million INR | -446.253% |
| Hikal Limited | 7.96 Billion INR | 47.551% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 86.872% |
| Novartis India Limited | -5.89 Billion INR | 170.931% |
| Wockhardt Limited | 18.27 Billion INR | 77.128% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 84.565% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 22753.312% |
| Neuland Laboratories Limited | -214.05 Million INR | 2052.102% |
| Morepen Laboratories Limited | -231.17 Million INR | 1907.569% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -3381.06% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -328.221% |